Anti-cytokine biological therapy in RA

Tsutomu Takeuchi

Research output: Contribution to journalArticlepeer-review


Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, resulting in estruction of joints. It has been demonstrated that the pro-inflammatory cytokines play a pivotal d role in the pathogenesis of RA, raising a hypothesis that the blockade of the cytokine cascade may provide a new therapeutic modalities in the disease. Biological agents inhibiting the function of inflammatory cytokines thus have been developed. Chimeric monoclonal antibody to TNFα(infliximab), full human antibody to TNFα (adalirnumab), TNF receptor 2-IgG fusion protein (etanercept), and IL-1 ra (anakinra) are new approved for RA in the states. In 2003, infliximab has just approved for RA in Japan, and we are now facing with the biological era. In this paper, the recent progress of anti-cytokine biological agents is reviewed.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalDrug Delivery System
Issue number2
Publication statusPublished - 2004
Externally publishedYes


  • IL-1
  • IL-6
  • TNF

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Anti-cytokine biological therapy in RA'. Together they form a unique fingerprint.

Cite this